Resistant Pseudomonas aeruginosa (CRPA) refers to carbapenem-resistant and
aeruginosa. In 2010, carbapenemases known as metallo-β-lactamases
(MBL) were first detected in the U.S.: New Delhi MBL (NDM) and Verona
integron-encoded MBL (VIM). Currently, the most common type of carbapenemase
seen in P. aeruginosa worldwide
is VIM. The genes encoding carbapenemases are often located on plasmids that
are easily spread between organisms. This webinar will discuss best practices
for the laboratory identification of CRPA and the importance of communication
between clinical labs and public health/labs about their test methods and
- Describe the growing threat of Carbapenem Resistant Pseudomonas aeruginosa (CRPA) and the role of the clinical laboratory in identifying and containing its spread.
- Review available test methods and best practices for CRPA identification and susceptibility testing.
- Identify CRPA testing services offered through the AR Laboratory Network and explain how they can support health care facilities.
A. Glover II, PhD, D(ABMM), MT(ASCP)
Assistant Director, Infectious Diseases
North Carolina Department of Health and Human Services
J. Simner, MSc, PhD, D(ABMM)
Associate Professor of Pathology
Johns Hopkins Medicine